Eos Energy Enterprises Inc vs Hims and Hers Health Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.17 (market cap $1.55B), while Hims and Hers Health Inc trades at $35.5 (market cap $8.60B). The key difference: Hims and Hers Health Inc is far larger — about 5.5× Eos Energy Enterprises Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | HIMS | |
|---|---|---|
Market Cap | $1.55B | $8.60B |
Sector | Energy | Health |
52-Week High | $19.19 | $66.18 |
52-Week Low | $4.29 | $14.52 |
Enterprise Value | $1.79B | $8.98B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.21, down 1.86% on the day, amid a bearish technical signal. The company reported a net loss of $969.65 million on $114.20 million revenue in 2025, with negative gross and net profit margins, but revenue growth is accelerating into 2026. Recent news highlights record quarterly revenue expectations and a $125 million investment for Frontier Power USA, signaling strong commercial momentum.
The outlook is mixed: accelerating revenue and a growing project backlog offer upside potential, but persistent losses and high debt-to-asset ratio of 91.87% pose significant financial risks. Analyst consensus is a 'Hold' with a $9.00 price target, reflecting cautious optimism balanced by execution concerns in the competitive energy storage market.
Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.
Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →